BridgeMD
A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma
EU CTIS ID: 2024-519437-27-02
What this study is testing
The primary endpoint is overall survival
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Signed informed consent • Histological verified glioblastoma • Recurrent GBM, previously treated according the STUPP regimen • No more than one line of chemotherapy (concurrent and adjuvant temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). • PS 0-1 • Age > 18 • Expected survival > 3 months • First progression after RT concurrent/adjuvant chemotherapy (STUPPS regimen). In case of early progression, then at least 3 months after termination of radiotherapy and at least 4 weeks after adjuvant chemotherapy. • No more than one line of chemotherapy
You likely can't join if
- • Previous therapy of recurrent GBM including temozolomide reinduction. • Previous use of biological drug targeting the VEGF-signaling pathway • Concurrent use of medication that can affect the interpretation of the results from the study, e.g. use of immunosuppressive drugs, except corticosteroids • Conditions (medical, social or physical) that may compromise proper information and/or follow-up • Other concurrent or previous cancer within 5 years, except adequately treated basal or squamous cell skin cancer, or cervical carcinoma in situ
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.